TL;DR: Aetna, a CVS Health company, modified CPB 0626 governing hematopoietic cell transplantation (HCT) coverage for thalassemia major and sickle cell anemia, effective October 8, 2025. If your team bills CPT 38240 (allogeneic HPC transplantation) or related stem cell codes for these diagnoses, this update changes what gets covered, what gets denied, and what documentation you need to support a claim.
The real issue here is precision. This Aetna hematopoietic cell transplantation coverage policy draws sharp lines between covered allogeneic procedures and non-covered autologous procedures. It also calls out specific experimental designations that will drive claim denial if you bill without understanding them. Get familiar with the rules before October 8, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia |
| Policy Code | CPB 0626 |
| Change Type | Modified |
| Effective Date | October 8, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology, Oncology, Bone Marrow Transplant Programs, Pediatrics |
| Key Action | Audit all pending and upcoming HCT authorizations against the updated donor type, age, and clinical criteria before October 8, 2025 |
Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025
CPB 0626 Aetna's coverage policy covers allogeneic hematopoietic cell transplantation—not autologous—for both thalassemia major and sickle cell anemia. That distinction is the single most important thing your billing team needs to internalize. Bill the wrong transplant type and you will get a denial.
Thalassemia Major (Homozygous Beta-Thalassemia)
Aetna considers allogeneic HCT medically necessary for children and young adults up to age 45 with thalassemia major. The primary requirement: the member meets the transplanting institution's written eligibility criteria.
If the institution has no written criteria on file, Aetna falls back to a specific donor requirement. The member must have a haploidentical to HLA-matched donor. That's the floor. Document donor type carefully—it will come up in prior authorization review.
Sickle Cell Anemia
For sickle cell anemia, the same age range applies: children and young adults. Again, the transplanting institution's written eligibility criteria govern coverage.
When no institutional criteria exist, Aetna requires both of the following for medical necessity:
| # | Covered Indication |
|---|---|
| 1 | A haploidentical to HLA-matched donor |
| 2 | A history of stroke, increased risk of stroke, or end-organ damage |
The "increased risk" language is not vague here. Aetna defines it. Qualifying factors include recurrent acute chest syndrome, recurrent vaso-occlusive crises, and red blood cell alloimmunization on chronic transfusion therapy. Your authorization request needs to name one of these specifically. Generic "high-risk disease" language will not hold up.
Adults Over Age 45
Members older than 45 fall outside the standard criteria. Aetna routes these requests to its National Medical Excellence (NME) unit. If your program treats adult HCT patients over 45, build that routing into your prior authorization workflow now. Standard PA channels will not work for this population.
HLA Typing and Donor Search Codes
When you bill CPT 86813, 86817, 86821, or 86822 for HLA typing, or CPT 38204 for donor search management, those claims must tie to a medically necessary allogeneic transplant. Reimbursement for these upstream codes depends on the transplant itself meeting criteria. If the transplant doesn't qualify, neither do the prep codes.
Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications
Three specific categories are experimental, investigational, or unproven under this coverage policy. Bill any of these and expect a denial.
Autologous HCT (CPT 38206, 38232, 38241)
Autologous transplantation—where the patient's own cells are harvested and reinfused—is not covered for either thalassemia major or sickle cell anemia. Aetna cites insufficient peer-reviewed evidence. This applies to children, young adults, and adults alike. There is no age exception and no clinical exception pathway described in the policy.
T-Lymphocyte Subset Testing at Engraftment (CPT 86359, 86360)
Using T-lymphocyte subsets at engraftment to predict acute graft-versus-host disease (GVHD) risk in thalassemia major patients is also experimental. CPT 86359 (T cells, total count) and CPT 86360 (absolute CD4/CD8 count with ratio) are explicitly not covered for this indication. Your team may bill these codes for other purposes—but not for GVHD risk prediction post-HCT in thalassemia major patients.
Treosulfan-Based T-Cell Depleted Haploidentical Stem Cell Transplantation (CPT 38210)
Treosulfan-based conditioning with T-cell depletion in haploidentical transplants is experimental for both sickle cell disease and transfusion-dependent thalassemia. CPT 38210 (specific cell depletion within harvest, T-cell depletion) falls here. Even if the transplant itself is allogeneic and haploidentical, this specific conditioning and preparation approach is not covered.
This is a subtle but expensive trap. Your transplant program may use treosulfan-based regimens routinely. Under this Aetna coverage policy, that approach is non-covered for these two diagnoses regardless of transplant type.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Allogeneic HCT for thalassemia major, ages 0–45, meets institutional criteria | Covered | 38205, 38230, 38240, S2150 | Institution must have written eligibility criteria on file |
| Allogeneic HCT for thalassemia major, ages 0–45, no institutional criteria | Covered | 38205, 38230, 38240, S2150 | Requires haploidentical to HLA-matched donor |
| Allogeneic HCT for sickle cell anemia, ages 0–45, meets institutional criteria | Covered | 38205, 38230, 38240, S2150 | Institution must have written eligibility criteria on file |
| Allogeneic HCT for sickle cell anemia, ages 0–45, no institutional criteria | Covered | 38205, 38230, 38240, S2150 | Requires HLA-matched/haploidentical donor AND stroke history, stroke risk, or end-organ damage |
| Allogeneic HCT for thalassemia major or sickle cell anemia, age 45+ | Route to NME | 38240 | Standard PA channel will not work; send to National Medical Excellence unit |
| Autologous HCT for thalassemia major or sickle cell anemia | Experimental / Not Covered | 38206, 38232, 38241 | Not covered for any age; insufficient clinical evidence |
| T-lymphocyte subset testing at engraftment for GVHD risk prediction (thalassemia major) | Experimental / Not Covered | 86359, 86360 | Not covered when used for this specific predictive purpose |
| Treosulfan-based T-cell depleted haploidentical transplantation | Experimental / Not Covered | 38210 | Not covered for sickle cell disease or transfusion-dependent thalassemia |
Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025
These are the steps your billing team and authorization staff need to complete before October 8, 2025.
| # | Action Item |
|---|---|
| 1 | Audit your active HCT prior authorization requests against the updated criteria. For any pending sickle cell anemia cases, confirm the clinical documentation names stroke history, stroke risk, or a qualifying end-organ damage factor—recurrent chest syndrome, recurrent vaso-occlusive crises, or red blood cell alloimmunization on chronic transfusion therapy. Vague language will trigger a denial. |
| 2 | Pull your transplant institution's written eligibility criteria and attach them to every authorization request. The policy uses institutional criteria as the primary gate. If your institution does not have documented written criteria, Aetna defaults to its own clinical requirements. Either way, the documentation must be in the file before the effective date. |
| 3 | Flag all autologous HCT cases for these two diagnoses and remove them from your billing queue. CPT 38206, 38232, and 38241 will not be covered. Any claims already submitted for autologous HCT under a thalassemia or sickle cell diagnosis should be reviewed for potential adjustment. |
| 4 | Remove CPT 86359 and 86360 from your HCT charge capture templates for thalassemia major. These T-lymphocyte subset codes are not covered when billed for GVHD risk prediction in this population. If your templates include them as standard post-transplant labs, update the templates before October 8, 2025. The code itself isn't banned—the specific indication is. Your documentation needs to support a different clinical purpose if you bill them at all. |
| 5 | Build an NME routing flag for any HCT patient over age 45. Standard prior authorization workflows will not get these requests to the right reviewer at Aetna. A denied auth here is procedural, not clinical—and it's avoidable. Talk to your authorization team about how to identify and escalate these cases. |
| 6 | Review your conditioning regimen documentation for treosulfan-based haploidentical transplants. If your program uses treosulfan with T-cell depletion (CPT 38210) for sickle cell or thalassemia patients, those cases need a coverage conversation before you bill. This is a high-dollar exposure point. Loop in your compliance officer to assess whether any current or upcoming cases fall into this experimental category. |
| 7 | Verify donor type documentation before billing CPT 38240. Aetna hematopoietic cell transplantation billing for allogeneic procedures requires that the donor match—haploidentical to fully HLA-matched—is documented in the clinical record. HLA typing codes 86813, 86817, 86821, and 86822 should be billed in the context of that documented workup. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0626
Covered CPT and HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 38204 | CPT | Management of recipient hematopoietic progenitor cell donor search and cell acquisition |
| 38205 | CPT | Blood-derived hematopoietic cell harvesting for transplantation, per collection; allogeneic |
| 38207 | CPT | Bone marrow or stem cell services/procedures |
| 38208 | CPT | Bone marrow or stem cell services/procedures |
| 38209 | CPT | Bone marrow or stem cell services/procedures |
| 38230 | CPT | Bone marrow harvesting for transplantation |
| 38240 | CPT | Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor |
| S2150 | HCPCS | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvested |
Not Covered / Experimental Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 38206 | CPT | Blood-derived hematopoietic cell harvesting for transplantation, per collection; autologous | Autologous HCT is experimental for thalassemia major and sickle cell anemia |
| 38210 | CPT | Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion | Treosulfan-based T-cell depleted haploidentical transplantation is experimental for sickle cell disease and transfusion-dependent thalassemia |
| 38232 | CPT | Bone marrow harvesting for transplantation; autologous | Autologous HCT is experimental for thalassemia major and sickle cell anemia |
| 38241 | CPT | Hematopoietic progenitor cell (HPC); autologous transplantation | Autologous HCT is experimental for thalassemia major and sickle cell anemia |
| 86359 | CPT | T cells; total count | Not covered for T-lymphocyte subset analysis at engraftment to predict GVHD risk in thalassemia major |
| 86360 | CPT | T cells; absolute CD4 and CD8 count, including ratio | Not covered for T-lymphocyte subset analysis at engraftment to predict GVHD risk in thalassemia major |
Chemotherapy Administration Codes (Related)
These CPT codes (96401–96450) cover chemotherapy administration related to conditioning regimens. Coverage depends on the transplant itself meeting medical necessity criteria. HCPCS J9000–J9999 chemotherapy drugs and Q0083 chemotherapy administration codes apply in the same way—covered when the underlying transplant qualifies.
| Code | Type | Description |
|---|---|---|
| 96401–96450 | CPT | Chemotherapy administration (full range) |
| J0895 | HCPCS | Injection, deferoxamine mesylate, 500 mg |
| J9000–J9999 | HCPCS | Chemotherapy drugs |
| Q0083 | HCPCS | Chemotherapy administration |
ICD-10-CM Codes
The policy document does not list specific ICD-10-CM diagnosis codes for this policy. Use the appropriate ICD-10-CM codes for homozygous beta-thalassemia and sickle cell anemia from your encoder, and confirm your payer's edits support the pairing with the transplant CPT codes listed above.
Get the Full Picture for CPT 38240
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.